Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-02-18 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2024年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024 年年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the full year 2024, including revenue, profit, and other key financial metrics. The document explicitly states that the data is preliminary, unaudited, and subject to the final audited annual report. It also includes explanations of performance changes and risk warnings. The document length is 1694 characters, which is relatively short and consistent with a brief earnings announcement rather than a full annual report. The document is not the full annual report (10-K) but a preliminary earnings release or performance summary. According to the filing definitions, an initial announcement of quarterly or periodical financial results with key highlights only fits the Earnings Release (ER) category. Therefore, this document is best classified as an Earnings Release (ER). FY 2024
2025-02-18 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock trading fluctuations for the company 江西新赣江药业股份有限公司. It details the stock price deviation over specific recent trading days, the investigation into possible causes including inquiries with major shareholders and management, and a statement confirming no undisclosed material information affecting stock price. The document references compliance with Beijing Stock Exchange trading rules and includes a risk warning to investors. It does not contain financial statements, earnings data, or detailed report content. It is a regulatory announcement about stock price behavior and related disclosures, fitting the category of Regulatory Filings (RNS) as it does not match other more specific categories like Earnings Release or Capital/Financing Update.
2025-02-16 Chinese
2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual earnings forecast (业绩预告) for Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It provides preliminary financial data for the full year 2024, including net profit estimates and reasons for performance changes. It explicitly states that the data are preliminary, unaudited, and subject to final confirmation in the 2024 annual report. The document is short (985 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-01-23 Chinese
第三届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the seventh meeting of the third board of directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results related to the extension of certain fundraising projects. There is no financial data or detailed report content, only a summary of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document is short (1149 characters) and does not contain financial statements or detailed management discussion, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive board meeting content rather than just a notice. Therefore, the correct classification is MANG with high confidence.
2025-01-15 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司部分募投项目延期实施的核查意见
Regulatory Filings
2025-01-15 Chinese
第三届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of a proposal regarding the extension of certain fundraising project timelines. It does not contain financial statements or detailed financial data, nor is it a full report. It is an official announcement of a board meeting decision, specifically from the Supervisory Board, which falls under Board/Management Information. The document is short (972 characters) and focuses on governance and management decisions rather than financial results or regulatory filings. Therefore, the appropriate classification is MANG (Board/Management Information).
2025-01-15 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.